The needle-and-thread suturing process surgeons use to create anastomoses has been a staple in the OR, largely unchallenged for nearly a century. New developments in minimally invasive and endoscopic surgery, particularly in coronary bypass procedures, have created the need for a tissue-closure technique that can produce high-quality anastomoses in small spaces with limited visualization. As a result, anastomotic device technology, a long dormant area of product development, has become a hot subject at clinical meetings, and numerous companies, from major device firms to start-ups, are exploring a range of different approaches. Coalescent Surgical, a start-up, is one of the first to market in this area, with an anastomotic device that uses an approach different than its competitors--a proprietary self-closing clip that replaces traditional sutures. Coalescent's challenge: to gain acceptance from surgeons, who are notoriously slow adopters of new technology. The company is betting that the advantages of its device, combined with being first to market, will enable it to survive what appears will be a stampede of competitors, including major players that have superior resources and existing relationships with surgeons.
by Stephen Levin
From the mid-16th century, when the father of modern surgery, French military barber-surgeon Ambroise Pare, introduced the idea of stitching...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
